MK
Michael King EF Hutton Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Apollomics
APLM
$5.99M
| $5.43 | $650 |
11,871%
upside
| Buy |
1 Apr ‘24
1 year ago |
|
2
Sonnet BioTherapeutics
SONN
$22.5M
| $3.29 | $1,179.20 |
35,742%
upside
| Buy |
23 Aug ‘23
2 years ago |
|
3
Lantern Pharma
LTRN
$43.8M
| $4.06 | $11 |
171%
upside
| Buy |
10 Aug ‘23
2 years ago |
|
4
Biomea Fusion
BMEA
$108M
| $1.81 | $32 |
1,668%
upside
| Buy |
26 Jun ‘23
2 years ago |
|
5
Jasper Therapeutics
JSPR
$43.1M
| $2.65 | $68.50 |
2,485%
upside
| Buy |
12 Jun ‘23
2 years ago |
|
6
Coeptis Therapeutics
COEP
$62.4M
| $12.95 | $200 |
1,444%
upside
| Buy |
25 May ‘23
2 years ago |
|
7
Werewolf Therapeutics
HOWL
$60.8M
| $1.33 | $8.30 |
524%
upside
| Buy |
25 May ‘23
2 years ago |
|
8
Regeneron Pharmaceuticals
REGN
$59.2B
| $558.44 | $862 |
54%
upside
| Buy |
1 May ‘23
2 years ago |
|
9
Exelixis
EXEL
$10.1B
| $37.69 | $24 |
36%
downside
| Buy |
28 Apr ‘23
2 years ago |
|
|
AGEN
10
Agenus
AGEN
$136M
| $4.26 | $166 |
3,797%
upside
| Buy |
28 Mar ‘23
2 years ago |
|
|
11
Biomea Fusion
BMEA
$108M
| $1.81 | $22 |
1,115%
upside
| Buy |
24 Mar ‘23
2 years ago |
|
12
Xencor
XNCR
$600M
| $8.41 | $42 |
399%
upside
| Buy |
24 Feb ‘23
2 years ago |
|
13
Alnylam Pharmaceuticals
ALNY
$59.6B
| $455.03 | $304 |
33%
downside
| Buy |
24 Feb ‘23
2 years ago |
|
14
Intellia Therapeutics
NTLA
$1.27B
| $11.84 | $116 |
880%
upside
| Buy |
24 Feb ‘23
2 years ago |
|
15
Compass Therapeutics
CMPX
$590M
| $3.44 | $10.30 |
199%
upside
| Buy |
16 Dec ‘22
2 years ago |
|
16
Scholar Rock
SRRK
$3.04B
| $31.58 | $24 |
24%
downside
| Buy |
23 Mar ‘22
3 years ago |
|
17
Salarius Pharmaceuticals
SLRX
$2.37M
| $4.65 | $12,000 |
257,965%
upside
| Buy |
11 Mar ‘22
3 years ago |
|
18
AnaptysBio
ANAB
$621M
| $22.19 | $46 |
107%
upside
| Buy |
8 Mar ‘22
3 years ago |
|
19
Agios Pharmaceuticals
AGIO
$2.12B
| $36.41 | $96 |
164%
upside
| Buy |
3 Mar ‘22
3 years ago |
|
|
AGEN
20
Agenus
AGEN
$136M
| $4.26 | $280 |
6,473%
upside
| Buy |
2 Mar ‘22
3 years ago |
|
|
21
Xencor
XNCR
$600M
| $8.41 | $55 |
554%
upside
| Buy |
24 Feb ‘22
3 years ago |
|
|
22
Exelixis
EXEL
$10.1B
| $37.69 | $42 |
11%
upside
| Buy |
18 Feb ‘22
3 years ago |
|
|
HURA
23
TuHURA Biosciences, Inc. Common Stock
HURA
$126M
| $2.52 | $5,250 |
208,233%
upside
| Buy |
20 Jan ‘22
3 years ago |
|
|
24
Biomea Fusion
BMEA
$108M
| $1.81 | $13 |
618%
upside
| Buy |
12 Jan ‘22
3 years ago |
|
25
Xilio Therapeutics
XLO
$36.1M
| $0.6957 | $36 |
5,075%
upside
| Buy |
10 Jan ‘22
3 years ago |
|